A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Phase of Trial: Phase I/II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Pegpleranib (Primary) ; Ranibizumab (Primary)
- Indications Von Hippel-Lindau disease
- Focus Adverse reactions
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 21 Dec 2018 Planned End Date changed from 30 Apr 2019 to 31 May 2020.
- 21 Dec 2018 Planned primary completion date changed from 30 Apr 2019 to 31 May 2020.